Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Citi
Covington
Cipla
Accenture
Farmers Insurance
Express Scripts
Julphar
Argus Health

Generated: July 17, 2018

DrugPatentWatch Database Preview

FORTOVASE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Fortovase patents expire, and when can generic versions of Fortovase launch?

Fortovase is a drug marketed by Hoffmann La Roche and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this compound. Additional details are available on the saquinavir profile page.
Summary for FORTOVASE
International Patents:40
US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: 35
Clinical Trials: 8
Patent Applications: 4,419
Formulation / Manufacturing:see details
DailyMed Link:FORTOVASE at DailyMed
Drug patent expirations by year for FORTOVASE
Generic Entry Opportunity Date for FORTOVASE
Generic Entry Date for FORTOVASE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for FORTOVASE
Synonyms for FORTOVASE
(2S)-N-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide
(2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide
(3S-(2(1R*(R*),2S*),3I,4athetav,8athetav))-N(sup 1)-(3-(3-(((1,1-Dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)butanediamide
(S)-N-((IS)-I-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide
127779-20-8
131176-13-1
149845-06-7 (monomethanesulfonate (salt))
1hxb
2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid
24223-EP2269989A1
24223-EP2272516A2
24223-EP2272825A2
24223-EP2298761A1
24223-EP2298783A1
24223-EP2305640A2
24223-EP2305680A2
24223-EP2314590A1
2fgu
2fgv
779S208
AB00514056
ABP000344
AC-26377
AC1L9ATC
AKOS000280831
Ambap127779-20-8
AN-32602
BC210734
BIDD:GT0323
BIDD:PXR0010
BPBio1_001373
BRD-K09963420-066-03-4
BSPBio_001248
Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-
Butanediamide, N1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R*(R*),2S*),3alpha,4aalpha,8aalpha))-
Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-
C-23431
CC-34367
CHEBI:63621
CHEMBL114
CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE
CS-1180
D00429
D0WI3T
DB01232
DTXSID6044012
Fortovase (TN)
Fortovase(TM)
GTPL4813
HMS2232L04
HSDB 7161
HY-17007
Invirase
Invirase (TN)
Invirase(TM)(monomesylate)
L3JE09KZ2F
LS-187081
MLS001195635
MLS001304735
MRF-0000273
N-tert.butyl-decahydro -2- [2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl) -L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N-tert.butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N-tert.butyl-decahydro-2[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N(1)-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide
N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide
NCGC00091469-02
NP-SQV
NSC722663
PLCG-SQV
Prestwick0_001114
Prestwick1_001114
Prestwick2_001114
Prestwick3_001114
QNC-ASN-HPH-DIQ-NTB
QWAXKHKRTORLEM-UGJKXSETSA-N
Ro 31 8959
Ro 31-8959
Ro 31-8959/000
Ro 318959
Ro-31-8959
Ro-318959000
ROC
saguinavir
SAQUINAVIR
Saquinavir (JAN/USP/INN)
Saquinavir [USAN:USP:INN:BAN]
saquinavir methanesulfonate
Saquinavir-poly(lactide-co-glycolide)
Saquinavir/
saquinavirmesylate(subjecttopatentfree)
SC-14020
Sch 52852
SCHEMBL6881
sequinavir
SMR000469157
SPBio_003114
SQV
SQV-poly(lactide-co-glycolide)
UNII-L3JE09KZ2F
W-5153
ZINC3914596

US Patents and Regulatory Information for FORTOVASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for FORTOVASE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0044 Belgium ➤ Sign Up PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
C0048 Belgium ➤ Sign Up PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
/1996 Austria ➤ Sign Up PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
70013 Netherlands ➤ Sign Up PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Teva
US Army
Johnson and Johnson
Deloitte
Fish and Richardson
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.